Zai Lab Past Earnings Performance
Past criteria checks 0/6
Zai Lab's earnings have been declining at an average annual rate of -14%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 51.6% per year.
Key information
-14.0%
Earnings growth rate
-5.7%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 51.6% |
| Return on equity | -44.5% |
| Net Margin | -116.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zai Lab makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 291 | -339 | 288 | 0 |
| 31 Dec 23 | 267 | -335 | 282 | 0 |
| 30 Sep 23 | 263 | -301 | 271 | 0 |
| 30 Jun 23 | 252 | -393 | 269 | 0 |
| 31 Mar 23 | 231 | -410 | 264 | 0 |
| 31 Dec 22 | 215 | -443 | 259 | 0 |
| 30 Sep 22 | 197 | -593 | 257 | 0 |
| 30 Jun 22 | 182 | -529 | 249 | 0 |
| 31 Mar 22 | 171 | -554 | 240 | 0 |
| 31 Dec 21 | 144 | -704 | 219 | 0 |
| 30 Sep 21 | 115 | -569 | 190 | -160 |
| 30 Jun 21 | 87 | -537 | 159 | -102 |
| 31 Mar 21 | 61 | -454 | 128 | -34 |
| 31 Dec 20 | 49 | -269 | 111 | 0 |
| 30 Sep 20 | 39 | -239 | 93 | 192 |
| 30 Jun 20 | 29 | -240 | 83 | 185 |
| 31 Mar 20 | 19 | -201 | 74 | 146 |
| 31 Dec 19 | 13 | -195 | 70 | 0 |
| 30 Sep 19 | 8 | -212 | 58 | 166 |
| 30 Jun 19 | 4 | -181 | 45 | 145 |
| 31 Mar 19 | 2 | -160 | 33 | 132 |
| 31 Dec 18 | 0 | -139 | 22 | 120 |
| 30 Sep 18 | 0 | -89 | 14 | 74 |
| 30 Jun 18 | 0 | -67 | 14 | 53 |
| 31 Mar 18 | 0 | -59 | 13 | 46 |
| 31 Dec 17 | 0 | -50 | 12 | 39 |
| 30 Sep 17 | 0 | -50 | 10 | 41 |
| 30 Jun 17 | 0 | -50 | 8 | 44 |
| 31 Mar 17 | 0 | -44 | 7 | 38 |
| 31 Dec 16 | 0 | -38 | 6 | 32 |
Quality Earnings: 9688 is currently unprofitable.
Growing Profit Margin: 9688 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9688 is unprofitable, and losses have increased over the past 5 years at a rate of 14% per year.
Accelerating Growth: Unable to compare 9688's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9688 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 9688 has a negative Return on Equity (-44.47%), as it is currently unprofitable.